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Introduction: The prognosis for patients with extensive-stage small
cell lung cancer remains poor. This trial was designed to evaluate the
efficacy and toxicity of maintenance sunitinib after platinum-etopo-
side chemotherapy.
Methods: Patients who demonstrated objective tumor response or
stable disease after four cycles of platinum plus etoposide chemo-
therapy were eligible. Sunitinib was given at 50 mg daily for 4
weeks of a 6-week cycle until disease progression or unacceptable
toxicity. The primary end point was 4-month progression-free sur-
vival (PFS) rate from initiation of sunitinib.
Results: Sixteen patients were enrolled. Responses to platinum-
etoposide were complete response (CR)/partial response (PR)/stable
disease (SD)  3/11/2. The median number of weeks on sunitinib
was 4 (range: 1.4–20). Reasons for sunitinib discontinuation were
disease progression (50%), toxicity (31%), and patient request
(19%). Median PFS from the start of sunitinib was 2.5 months (95%
confidence interval [CI], 0.8–3.1). Further accrual would have failed
to reach the target PFS rate, so the study was terminated. There were
no objective responses to sunitinib, but four patients (25%) had
disease stability for 15, 15, 17, and 20 weeks. Median PFS and
overall survival from the start of chemotherapy were 6.2 months
(95% CI, 4.1–6.5) and 8.2 months (95% CI, 6.2–14.7), respectively.
Grade 3 to grade 4 toxicity included thrombocytopenia (25%),
fatigue (19%), muscle weakness (13%), and hypothyroidism (6%).
Conclusions: Sunitinib did not seem to maintain disease stability
after response to chemotherapy. Sunitinib was discontinued in half
of patients due to toxicity or request to stop therapy. Although
disease stability with sunitinib was noted in four patients, this
approach does not seem to warrant further clinical study.
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For more than two decades, the standard therapy for patientswith extensive-stage small cell lung cancer (ES-SCLC) has
been platinum-based chemotherapy, which induces objective
tumor response in 60 to 80% of patients, median progression-
free survival (PFS) of 4 to 6 months, and overall survival
(OS) of 8 to 13 months.
Angiogenesis seems to be a relevant biological phe-
nomenon in SCLC as these tumors have a high microvessel
density, and preclinical studies indicate that SCLC cells
express functional vascular endothelial growth factor (VEGF)
receptors (VEGFR).1–3 Sunitinib is a small molecule inhibitor
of receptor tyrosine kinases involved in tumor proliferation
and angiogenesis, specifically platelet-derived growth factor
receptor (PDGFR), VEGFR, c-kit, FLT3, and RET. Given the
potential dependence of SCLC on VEGF/VEGFR activa-
tion, the use of an antiangiogenic agent such as sunitinib in
SCLC is an appealing therapeutic approach.
As nearly all patients with ES-SCLC develop disease
progression within months of initial treatment, prolongation
of PFS is a clinically meaningful end point for clinical trials
exploring novel agents. We hypothesized that sunitinib mainte-
nance therapy would delay or prevent recurrence and prolong
survival in patients who achieved an objective response or stable
disease with four cycles of induction chemotherapy. Therefore,
we designed a phase II study to evaluate the efficacy and
tolerability of maintenance sunitinib in patients with ES-SCLC
who did not progress after induction chemotherapy.
PATIENTS AND METHODS
Eligibility
Patients with histologically or cytologically docu-
mented ES-SCLC who had received no more than four cycles
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of front-line platinum plus etoposide chemotherapy and dem-
onstrated a response or stable disease were eligible. ES-
SCLC was defined as disease that extended beyond one
hemithorax and regional lymph nodes. Other requirements
included age 18 years, Zubrod performance status 0 to
2, absolute neutrophil count 1500/mm3, platelet count
50,000/mm3, serum calcium12.0 mg/dl, serum creatinine
2.0 mg/dl, total bilirubin 1.5 times the institutional upper
limit of normal, and aspartate aminotransferases (SGOT) and
alanine aminotransferases (SGPT) 2.5 times the upper limit
of normal. Patients were ineligible if they had grade 3
hemorrhage within 4 weeks of starting study treatment, any
history of gross hemoptysis, symptomatic, uncontrolled cen-
tral nervous system (CNS) disease, or required therapeutic
anticoagulation. The trial was approved by the local institu-
tional review boards, and signed written informed consent
was obtained from all patients.
Treatment
Patients began maintenance sunitinib 4 to 6 weeks after
day 1 of the fourth cycle of induction therapy to allow
recovery from chemotherapy and to permit the administration
of prophylactic cranial irradiation (PCI) if offered. Patients
were treated with sunitinib (SUTENT, Pfizer Inc.) 50 mg
orally once daily for 4 consecutive weeks followed by a
2-week rest period to form a 6-week cycle. Therapy contin-
ued until disease progression or unacceptable toxicity.
Dose Adjustment for Toxicity
Patients who developed grade 4 hematologic toxicity or
grade 3 or 4 nonhematologic toxicity had treatment held until
resolution to grade 2 or grade 1, respectively. Treatment
was then restarted at a dose of 37.5 mg. A second dose
reduction to 25 mg was also permissible. If sunitinib treat-
ment was interrupted for longer than 14 days during a 4-week
dosing period, then therapy was discontinued. The start of the
next cycle could be delayed up to 2 weeks if additional time
was required for recovery from treatment-associated toxicity.
Assessment of Response and Toxicity
Patients were considered evaluable for toxicity and
response if they received at least one dose of sunitinib. Scans
were performed after every two cycles to evaluate for re-
sponse/progression. Response was assessed according to
RECIST criteria.4 Sunitinib was discontinued if a patient
required a third dose reduction, developed progressive disease,
or had life-threatening, irreversible, or unacceptable toxicity.
Toxicity was graded according to the National Cancer Institute
(NCI) Common Toxicity Criteria v3.0 (http://ctep.cancer.gov/
reporting/ctc.html).
Statistical Analyses
The primary objective was to assess the 4-month PFS
rate in patients treated with maintenance sunitinib. A two-
stage Minimax Simon’s design was used. Based on historical
data, this treatment would be considered not interesting if the
4-month PFS rate from the start of sunitinib therapy was less
than 35%, and it would be of definite clinical interest if the
4-month PFS rate was more than 55%.5–7 With 21 patients in
stage 1 and 39 total patients, the two-stage design had a 5%
type I error and 80% power in testing the hypothesis, and the
probability of early termination would be 0.706 if the true
PFS rate was less than 35%. The trial was to be terminated at
stage 1 if 8 patients were progression free at 4 months.
PFS on sunitinib therapy was defined as the time from
initiation of sunitinib to progression of disease or death.
Other end points included response rate, toxicity, PFS from
initiation of induction chemotherapy, and OS defined as the
time from the initiation of induction chemotherapy to death
from any cause. All survival end points were estimated using
Kaplan-Meier method.8 The SAS System (Cary, NC) was
used for all analyses.
RESULTS
Sixteen patients were enrolled onto the study between
July 2007 and January 2009. Patient characteristics are sum-
marized in Table 1. Fifteen patients received four cycles of
carboplatin plus etoposide at standard doses, and one patient
received cisplatin plus etoposide. Three patients had a com-
plete response to induction chemotherapy, 11 had a partial
response, and two had disease stability. Six patients received
PCI after completion of chemotherapy and before initiation of
sunitinib.
Toxicity
All sixteen patients received sunitinib maintenance
therapy and were evaluable for toxicity analysis. Patients
received a median of 4 weeks of sunitinib (range: 1.4–20.0).
Disease progression was the main reason for discontinuation
of treatment (n  8, 50%). Five patients discontinued
sunitinib due to toxicity: grade 4 hypertension (n  1), grade
4 acute respiratory distress syndrome (n  1), persistent
grade 3 hand-foot syndrome (n  1), and grade 3/4 asthenia/
fatigue (n  2). Three patients received sunitinib for 2.9, 3.7,
and 20 weeks and then requested discontinuation of the drug,
mainly due to persistent asthenia. One of the patients who
opted to discontinue therapy refused further follow-up and
has been censored from survival analyses.
TABLE 1. Patient Characteristics
Characteristics No. (%)
Age (yr)
Median 66
Range 34–80
Sex
Male 8 (50)
Female 8 (50)
Performance status
0 5 (31)
1 10 (63)
2 1 (6)
Response to induction chemotherapy
CR 3 (19)
PR 11 (69)
SD 2 (12)
Received prophylactic cranial irradiation 6 (38)
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Toxicity is listed in Table 2. The most common grade
3 to grade 4 toxicities of sunitinib were thrombocytopenia
(25%), fatigue (19%), muscle weakness (13%), and hypothy-
roidism (6%). One patient had grade 4 thrombocytopenia
but did not experience bleeding. Three patients (19%)
required one dose reduction of sunitinib due to toxicity
during cycle 1. Of these, one patient required a second
dose reduction after cycle 2.
Response and Survival
No objective responses were identified with mainte-
nance sunitinib; however, four patients (25%) had stable
disease for 15, 15, 17, and 20 weeks. The median PFS from
the start of maintenance sunitinib was 2.5 months (95%
confidence interval [CI], 0.8–3.1) with a 4-month PFS rate of
13% (95% CI, 2–33%). The median PFS and OS from the
start of induction chemotherapy were 6.2 months (95% CI,
4.1–6.5) and 8.2 months (95% CI, 6.2–14.7 months), respec-
tively. The 1-year survival rate from the start of induction
therapy was 40% (95% CI, 15–65%). The intent-to-treat
Kaplan-Meier estimates of PFS and OS for the 16 patients are
presented in Figure 1. Because of slow accrual, a sufficient
number of events occurred for analysis in the first 16
patients. The 4-month PFS rate from the start of sunitinib
therapy would not have been able to reach our predeter-
mined threshold required for study continuation even if the
remaining five patients planned for stage 1 had been
accrued and had met the 4-month PFS mark. The study
was, therefore, discontinued early.
DISCUSSION
Preclinical data support the biologic activity and anti-
tumor effect of sunitinib in SCLC; however, the inhibition of
the specific receptor tyrosine kinase pathways that promote
its antitumor effect remains unclear. One presumed mecha-
nism is inhibition of the c-kit/stem-cell factor autocrine
growth pathway. The significance of c-kit inhibition was
evaluated by treating mice bearing human SCLC xenografts
with sunitinib or imatinib.9 Sunitinib resulted in significant
tumor growth inhibition, whereas the effect of imatinib was
less dramatic. Nevertheless, several clinical studies evaluat-
ing imatinib in patients with SCLC have failed to demonstrate
a clinical benefit.10–12 It is evident that SCLC does not have
significant dependence on the c-kit pathway for survival, and
its inhibition has not translated into clinical benefit for pa-
tients with SCLC.
The efficacy of sunitinib in SCLC preclinical models
may be conferred by targeting other receptors vital for cell
survival, such as VEGFR and PDGFR. For example,
sunitinib inhibited SCLC tumor growth at drug concentra-
tions that led to full PDGFR inhibition but only partial c-kit
inhibition.13 In contrast, sunitinib demonstrated greater inhi-
bition of c-kit and PDGFR than VEGFR and PDGFR- in
gastrointestinal stromal tumors (GISTs) refractory to ima-
tinib.14,15 These studies highlight the heterogeneity of tumor
signaling pathways between different tumor types and raise
concerns about using preclinical models to predict clinical
activity. The true contributions of these pathways to SCLC
tumorigenesis, survival, and metastasis remain unknown.
Antiangiogenic agents such as sunitinib may enhance
cancer cell death induced by chemotherapy through the inhi-
bition of compensatory pro-survival pathways.16,17 This ef-
fect may have been abrogated by our use of chemotherapy
followed by sunitinib in a sequential fashion. Nonetheless,
toxicities arising from this combination strategy may limit its
efficacy. Indeed, a phase IB study of the combination of
sunitinib 25 mg/d on days 1 to 14 with standard cisplatin and
etoposide reported prolonged neutropenia and an unaccept-
able rate of treatment-related mortality despite the use of
prophylactic granulocyte growth factors.18
The administration of sunitinib on a schedule of 4
weeks of treatment followed by 2 weeks of no treatment may
be suboptimal. Studies in renal cell carcinoma have shown
TABLE 2. Worst Toxicity from Sunitinib Experienced per
Patient (n  16) Grade
Toxicity 1–2 3 4
Anemia 3 0 0
Neutropenia 4 0 0
Thrombocytopenia 4 3 1
Nausea/vomiting 11 0 0
Diarrhea 4 0 0
Rash 4 0 0
Thyroid dysfunction 1 1 0
Hypertension 1 0 1
Muscle weakness/myalgia 4 2 0
Acute respiratory distress syndrome 0 0 1
Dyspepsia 3 1 0
Oral mucositis 2 1 0
Hand/foot syndrome 1 1 0
Taste alteration 3 0 0
Anorexia 8 0 0
Fatigue/decline in PS 9 2 1
PS, performance status.
FIGURE 1. Intent-to-treat Kaplan-Meier estimates for overall
survival (OS) and progression-free survival (PFS) for all pa-
tients, N  16 (median OS: 8.2 months; median PFS: 6.3
months from the start of chemotherapy).
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that circulating soluble VEGFR2 levels, which are elevated
pretreatment, decline after 4 weeks of sunitinib therapy but
increase over the 2-week break.19 In addition, FDG-positron
emission tomography studies have shown a reduction in
tumor metabolism while patients are taking sunitinib, but
tumor progression and increased FDG avidity during treat-
ment breaks.20,21 Finally, toxicity from sunitinib may have
obscured a small survival benefit. Six of the 16 patients
discontinued sunitinib during the first cycle due to toxicity or
patient request. Although all patients had a good performance
status at enrollment, patients with SCLC frequently have
difficulty tolerating further therapy. Prior chemotherapy and
PCI may also have amplified the toxicity of maintenance
sunitinib. Although sunitinib administration is convenient
compared with cytotoxic chemotherapy, the toxicity profile
should not be trivialized, especially in older patients who
previously received chemotherapy.
In conclusion, our trial demonstrated no clear improve-
ment in PFS or OS with maintenance sunitinib after platinum
plus etoposide induction therapy in patients with ES-SCLC.
Until we develop a better understanding of the molecular
defects that drive tumor survival, growth, and metastasis in
SCLC, an empiric treatment approach with sunitinib does not
seem to warrant further investigation.
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